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METABOLIC SYNDROME 
Abstract 
Seriously mentally ill patients who are taking second-generation antipsychotics have a high risk 
of metabolic complications, including obesity, diabetes mellitus type II, hypertension, and 
hyperlipidemia. Guidelines to screen for metabolic syndrome were established by the American 
Diabetes Association, American Psychiatric Association, American Association of Clinical 
Endocrinologists, and North American Association for the Study of Obesity (Clark, 2004). 
Compliance with implementing the guidelines to screen and monitor for metabolic syndrome 
vary from regular monitoring to little or none. This quality improvement project provided an 
educational intervention on screening and monitoring for metabolic syndrome in patients who 
were seriously mentally ill. The educational interventions were attended by 21 psychiatric-
mental health nurse practitioners. After the educational intervention was completed, there was 
significant improvement in provider knowledge as well as motivation to screen and monitor 
patients taking second-generation antipsychotic medications for metabolic syndrome. Education 
may motivate mental health providers to increase the use of metabolic screening guidelines for 
patients taking second-generation antipsychotic medications potentially improving long term 
outcomes for this patient population. 
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Metabolic Syndrome in Seriously Mentally Ill Patients: A Quality Improvement Project 
In recent years, there has been a growing concern regarding the negative impact of 
metabolic syndrome on the general health of the seriously mentally ill (SMI) population 
(Parrinello, 2012). SMI has been defined as having “a mental, behavioral, or emotional disorder 
that results in serious functional impairment currently or within the past year” (National Institute 
of Mental Health [NIMH], n.d.). Metabolic syndrome is defined as a “combination of medical 
conditions including at least three of the following: abdominal obesity, hypertriglyceridemia, 
low-level high-density lipid proteins, hypertension and high fasting plasma glucose level” 
(O’Toole, 2013, p.1127). Metabolic syndrome has been further defined by the National Institute 
of Health [NIH] (2016) as “a combination of risk factors that puts the individual at risk for 
cardiovascular disease” (NIH, 2016). In the United States, cardiovascular disease is the leading 
cause of premature death (NIH, 2016). The occurrence of metabolic syndrome is significantly 
higher (55%-60%) in individuals diagnosed with serious mental illness (Arms, Bostic, & 
Cunningham, 2014) compared to the general population (34%) (American Heart Association 
[AHA], 2014). 
The SMI population has been found to have the same risk factors for developing 
metabolic syndrome as the general population.  Risk factors include an unhealthy lifestyle with 
poor eating habits, a sedentary life or lack of exercise, and smoking. SMI patients who are 
prescribed second-generation antipsychotic (SGA) medication have an additional risk factor of 
weight gain, which can contribute to elevated risks of developing metabolic syndrome. 
Consequently, people with SMI have a higher risk for obesity, cardiovascular disease, and type II 
diabetes (Castillo, Rosati, Williams, Pessin, & Lindy, 2015). The SMI population diagnosed with 
cardiovascular disease has an increased chance of dying at nearly twice the rate of the general 
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population (DeHert, Schreurs, Vancampfort, & Winkel, 2009). People with SMI are usually 
prescribed SGA drugs, because these medications are successful in managing symptoms of their 
psychiatric illness. Unfortunately, these drugs lead to a higher chance of developing metabolic 
syndrome. Metabolic syndrome, along with the cardio-metabolic diseases, is the biggest 
contributor to death in the SMI population when compared with suicide and injury (Castillo et 
al., 2015).  
Background and Significance 
 According to Stahl (2013), SGA medications can cause an increase in appetite and weight 
gain. These symptoms are the start of metabolic syndrome. Weight gain often leads to obesity, 
insulin resistance, and dyslipidemia. Obesity increases the risk for developing diabetes, which 
has been shown to lead to cardiac disease. Some SGA medications (such as ziprasidone 
[Geodon]) cause an increase in triglyceride levels and insulin resistance in a way that is 
independent of weight gain (Stahl, 2013). For example, a person who starts taking SGA 
medications shows a rapid increase in triglyceride levels without significant weight gain, and, 
upon stopping the medication, the triglyceride levels decrease rapidly. The pharmacologic 
mechanism for these occurrences is not known. It is clear that some SGA medications can 
significantly increase triglyceride and insulin resistance that can lead to cardio-metabolic risks in 
some patients (Stahl, 2013).  
The primary adverse effect of taking SGA medications is weight gain leading to 
increased risk for metabolic syndrome, heart disease, and diabetes. These medications include 
olanzapine (Zyprexa) and, clozapine (Clozapine), which can cause the greatest weight gain. 
Risperidone (Risperdal) and quetiapine (Seroquel) are considered most likely to cause 
intermediate weight gain, and ziprasidone (Geodon) and aripiprazole (Abilify) cause the least 
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amount of weight gain (Muench & Hamer, 2010). Increased weight gain leading to an 
overweight condition or eventual obesity can lead to serious medical problems. According to 
Werneke, Taylor, & Sanders (2013), about one-third of people with schizophrenia who were 
treated with SGA medications develop metabolic syndrome; up to 15% had increased risk for 
developing type II diabetes. Their studies have shown that 70% of individuals treated with SGA 
medication have elevated serum lipids for their age (Werneke et al., 2013). The United States 
Food and Drug Administration (2004) requested all manufacturers of SGA medications to 
include a warning statement with the medication about the increased risk of hyperglycemia and 
diabetes. There is potential to reduce the morbidity and mortality for people with SMI by 
implementing initial health screenings and monitoring of patients on SGA medications. 
 Literature Review 
Advanced Nurse Practitioner Role 
 In 2004, the American Diabetic Association (ADA) and the American Psychiatric 
Association (APA) established a strong link between SGA drugs and a higher risk of developing 
metabolic syndrome. At that time, the ADA, APA, American Association of Clinical 
Endocrinologists and North American Association for the Study of Obesity recommended 
healthcare providers screen patients who are on SGA medications for early signs and symptoms 
of metabolic syndrome (Clark, 2004). Unfortunately, the advent of these metabolic monitoring 
guidelines has not always led to consistent implementation of these guidelines by healthcare 
providers (Cohn, 2013).  Parrinello (2012) found significant variation in the metabolic screening 
practices of SMI patients as the screening ranged from early screening to monitoring of SMI 
patients on SGAs to little or no monitoring of these patients. The screening and monitoring of 
metabolic syndrome in a psychiatric setting by psychiatric providers has been reported to be 
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inadequate. Additionally, it has been found that people with SMI who were screened for 
metabolic syndrome received referrals to primary care less often than people without mental 
illness (Parrinello, 2012).  
Metabolic syndrome, when undertreated or not diagnosed, can lead to severe outcomes, 
including heart attacks and/or strokes. One primary role of nursing is the prevention of disease 
and the management of medical complications (American Nurses Association [ANA], 2004).  
The role of the Advanced Nurse Practitioner (ANP) is to provide leadership and expertise in 
nursing practice to systematically improve standards of health care and outcomes (ANA, 2004). 
Consequently, ANPs need to be aware of the prevalence of metabolic syndrome in SMI patients 
who take SGA medications (McDaid & Smyth, 2015). As healthcare providers for a vulnerable 
population who are at high risk for metabolic syndrome, ANPs need to screen SMI patients for 
metabolic syndrome.  
Guidelines for Metabolic Monitoring  
  
 Psychiatric-mental health (PMH) NPs need to be aware of metabolic screening 
guidelines. Therefore, it is important that PMH-NPs implement the practice of monitoring 
metabolic parameters at initial SMI patient screening and throughout the course of care.  
According to the metabolic monitoring guidelines, minimal baseline screening should include: 
the patients’ own and family medical history, patients’ weight and height, the body mass index 
(BMI), waist circumference, blood pressure, fasting glucose (hemoglobin A1C), and fasting 
lipids before prescribing SGAs or immediately after the start of SGA’s (Clark, 2004). The 
metabolic monitoring guidelines recommend repeating the measurements of patients’ weight and 
calculating body mass index (BMI) in four weeks and in the next eight weeks. During week 
twelve, the metabolic monitoring guidelines recommend monitoring the patients utilizing the 
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same parameters evaluated in the initial metabolic screening. Afterwards, the metabolic 
monitoring guidelines recommend monitoring patients’ BMI every three months (Clark, 2004). 
Finally, the metabolic monitoring guidelines recommendation is to check all patients’ metabolic 
parameters annually (Clark, 2004).  
Identifying metabolic syndrome includes monitoring for increased abdominal girth (male 
greater than 40 inches and female greater than 35 inches waist circumference), elevated blood 
glucose levels (fasting glucose greater than or equal to 110 mg/dl), high triglyceride levels 
(fasting triglycerides greater than or equal to 150 mg/dl), high blood pressure (blood pressure 
greater than or equal to 130/85 mm Hg), and low levels of high-density lipoprotein cholesterol 
(male greater than 40 mg/dl and female less than 50 mg/dl) implementing the adult treatment 
panel III criteria for metabolic syndrome (National Institute of Health: National Heart, Lung, and 
Blood Institute, 2001). If patients with SMI meet any three of these five risk factors mentioned 
above they can be at risk for metabolic syndrome according to the adult treatment panel III 
criteria (National Institute of Health: National Heart, Lung, and Blood Institute, 2001). The 
mental health provider should make a referral to a primary care provider for further treatment.  
Barriers to Screening and Monitoring 
A review of the current barriers can be broken down into three main groups as to why 
screening and monitoring for metabolic syndrome in SMI patients varies. The barriers are 
directly related to the patient, providers, and the system (McDonell, Kaufman, Srebnik, 
Ciechanowski, & Ries, 2011). Understanding the current barriers to metabolic screening and 
monitoring compliance are important aspects of process improvement and will be addressed at 
the patient, provider, and system level. 
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Patient barriers. The main barriers to patients’ participation in metabolic screening are a 
lack of resources and alterations in cognition level related to their psychosis or chronic 
psychiatric illness (McDonell et al., 2011). Additionally, SMI patients are less able to recognize 
physical symptoms and less able to seek medical help (De Hert et al., 2011). Furthermore, SMI 
patients will not continue with their medical care because of impaired judgment caused by their 
chronic psychiatric illness.  
Providers’ barriers. McDonell et al. (2011) reported that the main barriers to mental 
health providers’ implementation of the metabolic monitoring guidelines (Clark, 2004) are lack 
of adequate training for treating metabolic syndrome and not having enough time to perform the 
required screenings and assessments. Mental health providers need to develop basic metabolic 
syndrome knowledge and incorporate this metabolic information into their practice (Cohn, 
2013). The mental health provider must be able to recognize who needs the initial screening such 
as patients who currently prescribed or likely to be prescribed antipsychotic medications (Cohn, 
2013).  
Lack of appropriate equipment in the mental health provider’s office and lack of time 
have been issues along with consistency in measuring abdominal girth. Studies have shown that 
waist circumference is rarely measured (DeHert et al., 2011). Therefore, mental health providers 
must have an appropriate weight scale, blood pressure cuff, and a tape measure for measuring 
waist circumference in their offices to screen for metabolic syndrome. 
Another main barrier for primary care providers is reported to be fear of treating patients 
with SMI and attitudes that these mental health patients are not within their scope of practice.  
Frequently, primary providers report the expectation that mental health providers should handle 
metabolic care (McDonell et al., 2011). In one study, the primary providers (100 of 154) stated 
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that it is the mental health provider’s responsibility to monitor for metabolic risk factors 
associated with SGAs (Mangurian, Giwi, Shunway, Fuentes-Afflick, & Perez-Stable, 2013). 
Ideally, once a patient’s metabolic risk factors have been recognized, the mental health 
provider then needs to make the appropriate referral to the primary care provider. It has been 
reported that communication between the primary care and mental health providers is often poor 
(Cohn, 2013). The ultimate care goal of SMI patients, who are a vulnerable population, is to give 
them psychiatric and health care in a comprehensive manner, which is a present-day challenge 
(De Hert et al., 2011). McKnight, Maudlin, Hatipoglu, and Citrome (2011) believe the standard 
of mental and primary health care is to practice continuous and precise clinical monitoring for 
effective long-term treatment.  
System barriers. The main system barriers include the idea that SMI patients have to see 
a mental health provider and primary care provider separately. The separate payment and 
qualification status means that some providers might not take Medicaid, for example, which 
causes some SMI patients to not pursue any additional health care. Another reason SMI patients 
may not interact regularly with the health care system is due to their insurance; Medicaid 
patients, for example, have a limited number of health care providers, which can increase the 
time spent waiting for appointment availability. 
The patient is often shuffled between the mental health and primary care systems. More 
often, the SMI patient has more contact with the mental health provider than the primary care 
provider. The mental health providers usually do not feel comfortable assessing for metabolic 
syndrome or they lack of up-to- date knowledge on metabolic syndrome. Since patients with 
SMI are more likely to be seen by mental health providers, these providers need to recognize 
risks for metabolic syndrome and then screen and monitor for metabolic syndrome (Cohn, 2013). 
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The rate of treatment for patients with SMI for metabolic syndrome is low compared to the 
general population. According to McDonell et al. (2011), in a large study of schizophrenic 
adults, who were treated with SGA medications for specific psychiatric diagnoses, the SMI 
individuals were not treated for medical (physical) diagnoses and illnesses. This study revealed 
that at least 30% with diabetes, 62.4% with hypertension, and 88% with abnormal cholesterol 
were not adequately treated with medications (McDonell et al., 2011).  
Documentation barriers. Despite the creation of metabolic monitoring guidelines 
(Clark, 2004), screening for metabolic syndrome continues to be a challenge to mental health 
providers and to treating metabolic syndrome. Tracking the adverse effects of SGA medications 
is the responsibility of the mental health provider. The provider should screen and monitor for 
metabolic syndrome and make needed referrals for pertinent abnormal findings as a result of 
screening (Brunero & Lamont, 2009). 
 Implementing a metabolic screening tool based on the metabolic monitoring guidelines 
(Clark, 2004) is imperative for mental health providers to monitor patients on SGAs. Mental 
health providers who practice the metabolic monitoring guidelines achieve best practice 
standards that ensure the best outcomes in psychiatric care (Parrinello, 2012).  Therefore, if the 
patient meets the criteria for the minimal number of metabolic risk factors, an appropriate 
medical referral can then be made.  
Purpose 
 The purpose of this quality improvement project was to provide information on metabolic 
screening for patients with SMI based on current guidelines to PMH-NPs. Participants will 
demonstrate:   
1. Increased knowledge of metabolic screening guidelines. 
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2. Increased intention to implement metabolic screening guidelines. 
3. Satisfaction with the metabolic screening tool and toolkit. 
Educational Intervention using an Evidence Based Practice Model 
The educational intervention on screening and managing metabolic syndrome in SMI 
patients was to help PMH-NPs incorporate metabolic screening into their daily practices. 
Another aim of the educational approach was to increase adherence of metabolic screening in 
PMH-NPs’ practice so metabolic syndrome can be identified earlier along with the 
implementation of timely treatment in the event that a referral is needed. The National Health 
Service states that short educational interventions are a common way to engage nurse 
practitioners in thinking about ways to change their practice to improve health outcomes for 
patients (White, Hemingway, & Stephenson, 2014). The plan should include information on 
metabolic screening, monitoring, and basic treatment guidelines in SMI patients who are taking 
SGA medications.  
The educational intervention followed the Plan-Do-Study-Act (PDSA) model as a 
framework for this quality improvement project. The PDSA is a scientific method where an idea 
can be implemented on a small scale leading to improvement (AHRQ Healthcare, 2013). The 
PDSA model was used to develop an educational approach to managing metabolic syndrome in 
SMI patients. The PDSA model began with four basic ideas: 
1. Plan- identify the problem and proposed implementations 
2. Do- implement the educational intervention to participants and collect the pre-and 
post-design 
3. Study- looks at the data analysis and interprets the pretest and posttest results along 
with the review feedback to see if objectives were met. 
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4. Act- make changes to the educational intervention based on the feedback and post 
survey where a new PDSA cycle begins. Educational intervention will be used in the 
future for more educational offerings.  
Methods 
Design 
This quality improvement project used a non-randomized one-group pretest-posttest 
quasi-experimental design (Burns & Grove, 2005). The educational intervention was held at 
Providence Alaska Medical Center (PAMC) and Girdwood, Alaska. The participants consisted 
of a convenience sample of 21 PMH-NPs from Anchorage, Alaska. The educational intervention 
compromised of five multiple-choice questions, about a one-hour educational intervention along 
with post evaluation survey. 
Ethical Considerations 
This project consisted of an educational intervention provided to PMH-NPs where there 
were no risks to the participants attending the educational intervention. The participants had a 
choice to participate in the educational intervention and to complete the pretest and posttest and 
survey of the educational intervention. The return of their completed tests and survey implied 
consent. The test was anonymous and only one question had a participant identifier in regards to 
their specialty area.  
The project was approved by the University of Alaska Anchorage Institutional Review 
Board (IRB) (Appendix H). The educational sessions were held at PAMC; therefore, the project 
was also approved by the Providence Alaska Medical Center IRB and approved as no human 
subject research (Appendix I). 
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Measures 
A short multiple-choice survey (Appendix B) used in a prior study (Arms et al., 2014) 
measured participant knowledge of metabolic screening guidelines before and after the 
intervention. Permission from Tamatha Arms, DNP, PMHNP-BC, NP-C to use the survey is 
shown in Appendix C. The Arms et. al. (2014) survey was used for both the pretest and the 
posttest measure. The surveys consisted of five multiple-choice questions. The test score was 
based on how many questions the participants’ answered correctly. If the participants’ answered 
all five questions correctly, then that equated to a score of 100%. The post survey included four 
close-ended questions with one open-ended question where the participants could answer with 
their personal response. A metabolic syndrome toolkit along with metabolic screening tool was 
provided to the participants based on the evidence- based practices and literature search on 
metabolic screening guidelines. The post survey questions were developed by the principal 
investigator and shared with the committee chair to establish face validity. 
Plan 
During the planning phase an educational intervention was planned based on literature 
search and best evidence-based practices. The important points of the literature search reported 
there was a lack of knowledge, time, and an efficient way to document data when screening for 
metabolic syndrome as well as collaborative care. A metabolic syndrome intervention (Appendix 
A) was developed incorporating the important points from the literature search and best 
evidence-based practices for managing metabolic syndrome in SMI patients taking SGAs. Before 
the presentation, a short multiple-choice test was given to the participants before and after the 
intervention. A post survey focusing on the educational information as well useful metabolic 
screening handout materials were provided to the participants after the intervention. The 
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principal investigator reviewed the posttest responses and any suggestions considered for the 
next metabolic syndrome intervention. 
Do 
In the Do phase, post-evaluation questions for the educational intervention were 
completed (Appendix D). Flyers (Appendix E) were distributed at PAMC and at other local 
mental health facilities in Anchorage, Alaska. The supervisor and nurse educator of the Mental 
Health Unit at PAMC prepared reminder announcements for the Mental Health Department one 
day before the educational intervention was presented. The metabolic syndrome toolkit 
(Appendix F) was created to provide participants with a handout on critical information in the 
metabolic syndrome intervention.  The participants were recruited by advertising the intervention 
at PAMC and local mental health facilities in Anchorage, Alaska.   
Before starting the educational interventions on April 14 and 15 at PAMC and April 16 in 
Girdwood, Alaska, the principal investigator provided the participants with a pretest, which took 
about five minutes to complete. Once the pretests were collected, the principal investigator 
presented the educational intervention via a Power Point presentation. This presentation took 
approximately 30 minutes followed by a 15-minute question and answer period. The principal 
investigator provided the participants with a “toolkit” for screening and managing patients with 
metabolic syndrome along with a metabolic syndrome-screening tool (Appendix G). Afterwards, 
the principal investigator provided the participants with a posttest and post survey of the 
intervention to complete. The principal investigator was interested to receive feedback from the 
participants if the educational intervention was presented accurately and motivate them to 
increase metabolic screening in their practice. The educational material will be used for a larger 
more diverse audience in the future. 
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Study 
In the study phase, the principal investigator reviewed the results of the data collected 
from the educational intervention pretests and posttests. Paired t tests were used to analyze the 
tests. The pretest average score of 21 participants was 52.3 percent with a SD of 16.0. The 
posttest average score of 21 participants was 93.3 percent with a SD of 9.6. Please see Figure 1: 
Pretest and Posttest Scores. 
 
 
Figure 1. Test scores: pretest scores are shown in gray and posttest scores are shown in 
black. 
 
Analysis included computing the percent correct for each question. Seven participants 
answered the first question correctly. This question asked what “the National Institute of Health 
defines metabolic syndrome as a combination of risk factors for...” The answer was 
cardiovascular disease. Five participants answer the second question correctly. This question 
asked what “the most significant factor of metabolic syndrome is…” The answer was central 
adiposity. Twenty participants answer the third question correctly. This question asked what 
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“early identification of metabolic syndrome is critical in…” with the answer being “avoiding 
progression to chronic disease and mortality”. The fourth question was answered correctly by all 
of the participants. This question asked what “The Clinical Antipsychotic Trial of Intervention 
Effectiveness study showed which relationship between antipsychotic medication and weight 
gain?” The answer was antipsychotic medications cause weight gain. Only two participants 
answer the fifth question correctly. This question asked, “An outcome from the educational 
intervention was found to be…” The answer was improved interprofessional collaboration.  
The posttest results showed a significant improvement in the responses to the questions. 
All of the participants answered questions 1, 3, and 4 correctly.  Sixteen participants answered 
question two correctly. Eighteen participants answer question five correctly. Please see Figure 2: 
Comparison of Pretest & Posttest Questions.  
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Figure 2. Questions (1-5) in percentages. Pretest questions (1-5) in black. Posttest questions (1-
5) in gray.  
 
 SPSS statistics version 21 was used to analyze the data. The final analysis with a paired sample t 
test demonstrated that the participants’ posttest score (M=93.3, SD= 9.6) was higher compared to 
the pretest score (M=52.3, SD = 16.0), t (20) = -9.168, p < .01.  
The post survey feedback for Questions 1-4 was consistently answered yes with some 
additional comments from the participants. Question 1 asked, the metabolic screening 
information presented clearly? Question 2 asked, do you think metabolic management content 
was presented clearly? Question 3 asked, did the lecture motivate you to increase metabolic 
screening in your practice? Question 4 asked, did the lecture increase your knowledge on 
screening and monitoring for metabolic syndrome? Some participants made additional comments 
such as: “plan to practice metabolic screening including waist circumference”, “plan to use the 
screening tool,” and “plan to practice”. Most participants stated “no” or “none” on question 5, 
which asked for any other suggestions for this educational lecture on metabolic syndrome? Other 
comments from the participants included: “fantastic job”, “great work”, “I really liked the tool 
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kit!”  “informative”, “more time”, “thank you for the metabolic toolbox”, “good information”, 
and “wonderful, thank you”.  
Act 
Changes to the educational intervention were implemented. The major change that was 
identified was the original test given on separate pieces of paper which made difficultly in 
distinguishing to whom the pretest and posttest belonged. Therefore, these test results were not 
used in this study. From this experience, the principal investigator developed a numeric system 
and assigned a number to each participant’s test. The numeric system proceeded smoothly and 
left no confusion as to which test belonged to which participant. Afterwards, the principal 
investigator started another cycle of the PDSA model. This was done after the principal 
investigator reviewed the test on one paper with the pretest on one side and the posttest on the 
other side. The findings have been shared with the management team and the Nurse Educator on 
the Mental Health Unit at PAMC. Implications for practice based on positive outcomes of this 
study where that the participants’ increased their knowledge in metabolic screening and 
expressed motivation to implement metabolic screening guidelines for the SMI patient. The 
educational lecture will be used for future presentations locally and hopefully in a more diverse 
population.  
Dissemination 
This quality improvement project was presented through a Power Point presentation at 
PAMC, Anchorage and Girdwood, Alaska. A poster presentation of the Metabolic Screening 
Project with the results of the study will be presented at the Alaska Nurse Practitioner conference 
in Anchorage, Alaska, in September 2017 and the Alaska Psychiatric Association in Girdwood, 
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Alaska, April 2017.  A poster presentation was also planned for staff meetings at local mental 
health facilities in Anchorage.   
Significance to Nursing 
Metabolic syndrome, when undertreated or not diagnosed, can lead to severe outcomes, 
such as cardiac disease. PMH-NPs need to be aware of the prevalence of metabolic syndrome in 
SMI patients who take SGA medications (McDaid & Smyth, 2015). As providers for a 
vulnerable population who are at high risk for metabolic syndrome, ANPs need to screen SMI 
patients for metabolic syndrome in accordance with the guidelines. In one study where metabolic 
syndrome screening was done on 141 participants with SMI in New York, 53% were diagnosed 
with metabolic syndrome. Only nine participants in this study had no risk factors (Castillo, 
Rosati, Williams, Pessin, & Lindy, 2015). This project was able to improve knowledge of 
metabolic screening in this population as well as motivate PMH-NPs to implement metabolic 
screening in their practice. 
Limitations 
 There were several limitations in this study including, small sample size, posttests given 
immediately after the educational intervention, and the post survey. In regards to a small sample 
study of 21 Alaskan participants, further studies with a larger PMH-NPs group in Alaska would 
be beneficial. The posttest was given immediately after the educational intervention. A further 
study can be done with having PMH-NPs taking the test later (after one month) to determine if 
they retained the material taught in the educational intervention. Also, the post survey feedback 
questions were closed-ended questions with the exception of the last question which was an 
open-ended question. Having more open-ended questions could have provided more richness in 
the responses and provide more meaningful feedback from the participants. The researcher could 
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have used a Likert Scale for the post evaluation questions to obtain more accurate data. This 
small sample study of 21 Alaskan participants demonstrated motivation to use metabolic 
screening and monitoring in their practice. Further studies can be done on the Alaskan PMH-
NPs’ experiences implementing metabolic syndrome screening in SMI patients.  
Summary and Conclusions 
Metabolic screening has the potential to make a difference in SMI patients and improve 
their healthcare outcomes and quality of life. Unfortunately, there are barriers as to why 
metabolic screening is not practiced by providers specifically PMH-NPs. Despite metabolic 
monitoring guidelines (Clark, 2004), there is still a gap in providing metabolic screening in at-
risk populations for SMI patients taking SGAs.  
In conclusion, Alaskan PMH-NP participants demonstrated significantly improved 
knowledge and reported they were motivated to increase metabolic screening in their practice. 
They reported their knowledge was enhanced by this educational intervention. They also found 
the metabolic toolkit and screening tool were helpful for their practices. Education may improve 
guideline compliance and improve the health of those with SMI who must take medications that 
cause metabolic complications. This practice improvement project reflects the positive 
implications that education and user-friendly practice tools can have on improving patient 
outcomes.  
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Appendix A 
Educational Intervention 
 Goal of this Learning Activity:  Is to provide nurse practitioners (NP’s) with knowledge on 
metabolic screening and monitoring of seriously mentally ill (SMI) patients who are at high risk 
for metabolic syndrome while taking second-generation antipsychotic (SGA) medications. The 
importance of collaboration with a primary medical provider will be addressed. 
Target Audience:  PMH-NP’s who work with the SMI population. 
Learning Objectives:  
1. Describe the significance of early metabolic screening for SMI patients who are 
prescribed second-generation antipsychotic medications for the first time or who are 
already on antipsychotic medications.  
2. Describe the national metabolic monitoring guidelines for metabolic screening and 
monitoring of patients with SMI who are taking SGAs. 
3. List the risk factors and the metabolic syndrome parameters that need to be considered 
for patients with SMI who are taking SGA medications. 
4. Identify barrier to monitoring patients with SMI who are taking SGA medications. 
5. Implement and use the metabolic monitoring tools according to the American Psychiatric 
Association/American Diabetic Association and other associations’ guidelines (2004).  
6. Make appropriate referrals to medical providers for treatment of metabolic syndrome in 
patients with serious mental illnesses.  
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Script Planned for the Intervention 
 The prevalence of metabolic syndrome in SMI patients taking SGA is rising (estimated to 
be double) in comparison to the general population. The SMI patients on SGA medications have 
an increased risk for metabolic complications like central obesity and insulin resistance. Theses 
metabolic abnormalities increase the risk for Diabetes type II and cardiovascular disease. 
Metabolic syndrome is a group of risk factors that occur together, which include abdominal 
obesity, hypertension, diabetes type 2, and dyslipidemia. Metabolic syndrome is clinically 
identified if at least has any three of the following five risk factors implementing the Adult 
Treatment Panel III (2001):  
• Central obesity (Male > 40 inches’ waist circumference and female > 35 inches’ waist 
circumference) 
• Fasting triglycerides > 150 mg/dl 
• HDL cholesterol (Male < 40 mg/dl and Female < 50 mg/dl) 
• Blood Pressure > 130/85 mm Hg 
• Fasting glucose > 110 mg/dl 
Patient with SMI like schizophrenia have an increased morbidity and mortality due to 
cardiovascular disease. The risk factors for these patients are: genetic disposition, lifestyle 
choices poor diet, lack of physical activity, smoker, and drug/substance abuse, chronic illness 
like diabetes mellitus, and effects of SGA medications. Patient with SMI are more likely to be 
overweight, smoke, and have increased rates of diabetes, hypertension, and abnormal lipid serum 
levels.    
Second-generation antipsychotic medications have a higher risk for metabolic syndrome 
because of the adverse effect for weight gain. Weight gain in SGA medications usually occurs 
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during the drug therapy and usually associated with increased risk for diabetes mellitus and 
dyslipidemia. Second generation antipsychotic medications commonly used are olanzapine 
(Zyprexa), clozapine (Clozaril), risperidone (Risperdal), quetiapine (Seroquel), ziprasidone 
(Geodon), and aripiprazole (Abilify). SGA medications are more commonly prescribed than first 
generation antipsychotics because of less extrapyramidal effects. Olanzapine and clozapine have 
a high weight gain, high dyslipidemia, and high rate of diabetes mellitus (DM) type II. Risperdal 
and quetiapine have a moderate weight gain, low for dyslipidemia and DM type II. Ziprasidone 
and aripiprazole are low weight gain, low dyslipidemia, and low DM type II. 
The ADA/APA and other associations developed guidelines in 2004 to screen and 
monitor for clients who are taking SGA medications. Mainly to help clinicians screen for at-risk 
clients by doing an initial screen and continue to monitor the client while still prescribed a SGA 
medication. To screen for metabolic syndrome must first do a baseline of personal and family 
history, weight (BMI), waist circumference, blood pressure, fasting glucose/hemoglobin A1C, 
and fasting lipids. Then based on the metabolic monitoring guidelines (2004) will continue to 
monitor for metabolic syndrome.   
Abdominal obesity is the most accurate parameter to measure correctly for the presence 
of metabolic syndrome. Increased glucose levels are more specific parameter to identify for 
metabolic syndrome presence. When these two parameters are measured usually 100 percent of 
these clients are identified with metabolic syndrome. Need to meet there of the five identified 
risk factors. 
 At baseline assessment consider the modifiable risk factors like overweight, obese, 
tobacco, alcohol and drug abuse, sedentary lifestyle, and poor dietary habits. Also consider other 
medications that can be liable for increased weight gain. Keep in mind that glucose and lipid 
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abnormalities can occur without weight gain. When prescribing SGA medications be considerate 
of the client’s risk factors and current metabolic state, the antipsychotic metabolic rate, and avoid 
usage of other medications that can cause weight gain.  
 First-line interventions are lifestyle modifications to decrease cardiovascular risks in 
patients with metabolic syndrome. Usually the focus is dietary interventions, smoking cessation, 
and increased physical activity. Educate the patients on possible side effects of the medications, 
the signs and symptoms of diabetes, and the patient’s illness. Provide safe ways to weight 
reduction for overweight/obese patients like heart healthy diet, smoking cessation or reduction 
for tobacco users. Safe ways to increase physical activity in their life. Referrals are made if 
patient has elevated glucose levels, lipid abnormalities, and hypertension. Also, can make a 
referral to see a nutritionist if overweight or obese. 
 Continue to monitor patients based on the metabolic monitoring guidelines for metabolic 
syndrome. If metabolic syndrome is identified then review modifiable risk factors, encourage the 
education given on modifiable risk factors, and refer the patient for evaluation and treatment of 
the identified risk factors or abnormal lab values to primary provider. Also can refer the high risk 
clients with severe obesity to dietitian.  
 The goals for metabolic monitoring according to the guidelines is early identification of 
diabetes, dyslipidemia, and hypertension. Also to identify the patients who are at high risk for 
metabolic syndrome and to provide preventative measures like increasing physical activity and 
promoting health. Health professionals like NP’s, need to recognize metabolic syndrome is a risk 
marker for patients with SMI treated with SGA’s. To prevent metabolic syndrome or identify 
early metabolic risk factors must collaborate care:  mental health providers with primary care 
providers and other specialized clinicians.   
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Appendix B 
Pretest/Posttest 
Specialty Area:  Please circle the one specialty that most identifies you professionally. 
Psychiatric-Mental Health NP      Psychiatric-Mental Health RN         Educator    
1. The National Institute of Health defines metabolic syndrome as a combination of risk 
factors for: 
A.  Hyperglycemia 
B.  Hyperlipidemia 
C.  Digestive disease 
D. Cardiovascular disease 
2. The most significant risk factor of metabolic syndrome is: 
A.  Hypertension 
B. Hyperlipidemia 
C. Central adiposity 
D. Atherosclerosis 
3. Early detection of metabolic syndrome is critical in: 
A.  Avoiding progression to chronic disease and early mortality. 
B. Determining doses of antipsychotic medications.  
C. Determining psychotherapy strategies. 
D. Limiting progression to acute disease and the risk of hospitalization.  
4. The Clinical Antipsychotic Trial of Intervention Effectiveness study showed which 
relationship between antipsychotic medication and weight gain? 
A. Inconsistent relationship. 
B. Antipsychotic medications cause weight loss. 
C. Antipsychotic medications cause weight gain. 
D. There is no effect on weight. 
5. An outcome from the educational intervention was found to be: 
A.  Resistance from counselors to assess BMI. 
B.  Reluctance of primary care practitioners to accept patients with mental illness. 
C. Improved interprofessional collaboration.  
D. Identification of the scarcity of preventative health care for this patient population. 
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(Permission granted to use questions from Tamatha Arms, DNP, PMHNP-BC, NP-C) 
 
Arms, T., Bostic, T., & Cunningham, P. (2014). Educational intervention to increase metabolic 
syndrome in patients at community mental health centers. Journal of Psychosocial 
Nursing, 52(9), 32-36. 
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Appendix C 
Approval Letter 
 
From: Arms, Tamatha E. [mailto:armst@uncw.edu]  
Sent: Wednesday, April 13, 2016 3:12 AM 
To: Annabel K Moreno <amoreno@uaa.alaska.edu> 
Subject: Re: Request to use questions 
 
Annabel,  
 
I'm glad to hear that you will be doing DNP work around this area as well.  
You can use the questions as long as you cite the reference please. 
 
Tamatha (Tammy) Arms, DNP, PMHNP-BC, NP-C 
Nurse Faculty Leadership Academy scholar 
UNCW CHHS School of Nursing 
McNeil office 2034A 
910-962-7192 
armst@uncw.edu 
 
 
 
“NOTICE: Emails sent and received in the course of university business are subject to North Carolina Public Records 
Act (N.C.G.S. §132-1 et seq.) and may be released to the public unless an exception applies.” 
 
 
From: Annabel K Moreno <amoreno@uaa.alaska.edu> 
Sent: Wednesday, April 13, 2016 2:00 AM 
To: Arms, Tamatha E. 
Cc: jpn@healio.com 
Subject: Request to use questions  
  
To whom it may concern, 
 
My name is Annabel Moreno & I am a graduate student (Psychiatric-Mental Health NP) at 
University of Alaska Anchorage seeking permission to use your CME questions on your article. I 
am only using 5 questions. Please let me know if that is ok to use in my graduate project on 
Metabolic Syndrome Screening in Serious Mental Ill Patients. 
 
Thank You for your consideration, 
 
Annabel Moreno, BS, RN, Psychiatric-Mental Health NP-student 
University of Alaska Anchorage  
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Appendix D 
Post Survey  
1. The information on metabolic screening was presented clearly? 
 
2. Do you think the content on metabolic management was presented accurately? 
 
 
3. Did this lecture motivate you to increase metabolic screening in your practice? 
 
 
4. Did the lecture increase your knowledge on screening and monitoring for metabolic 
syndrome? 
 
 
5. Any other suggestions for this educational lecture on metabolic syndrome? 
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Appendix E  
 Flyer 
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Appendix F 
 Toolkit 
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Appendix G 
Metabolic Syndrome Screening Tool Patient Name: _____________________________________________  Date of Visit: _______________________________________________ 
 Height (inches): ______________________________ 
 
Metabolic Syndrome considered positive for MS if 3 or more (*) risk 
criteria present 
Measure Risk Criteria Baseline ___/___/___ ___/___/___ ___/___/___ ___/___/___ ___/___/___ ___/___/___ 
*Waist 
Circumference 
Men > 
40 inch 
Women 
> 35 inch 
       
*Blood 
Pressure 
>130/85 
mmHg        
Weight N/A        
BMI BMI > 30        
Measure Risk Criteria Baseline ___/___/___ ___/___/___ ___/___/___ ___/___/___ ___/___/___ ___/___/___ 
*Fasting 
Plasma 
Glucose 
> 100 
mg/dl         
*Fasting 
Triglycerides 
> 150 
mg/dl        
*Fasting 
HDL 
Cholesterol 
Men < 
40 mg/dl 
Women 
< 50 
mg/dl 
       
Fasting 
LDL 
Cholesterol 
> 100 
mg/dl        
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Appendix H 
UAA IRB Waiver 
  
INSTITUTIONAL REVIEW BOARD REQUEST FOR DETERMINATION OF HUMAN 
SUBJECTS RESEARCH 
   
Consider your activity (research project, thesis, study, task, assignment) and the data (information) 
you, a member of your research team, or a collaborator, plan to collect, when responding to these 
questions.   
Activity Examples: surveys, questionnaires, focus groups, interviews  passive observation of public behavior (in physical or 
online environments, including social media)  experiments using electronic equipment or gaming techniques  the use of 
instruments or devices, including phones, to collect or monitor or influence behavior  diet, nutrition studies, or taste tests  
physical or biomedical procedures, such as imaging, scanning, blood collection, anthropomorphic procedures  studies 
examining individuals’ responses to manipulation of their physical or online environment  studies examining effectiveness of 
educational tools or curricula  pilot studies and other preliminary studies  any other activity that involves observation of, or 
interaction with, individuals to gather information for research.  
Enter a response for each question, complete Section B on Page 2 and send to 
simumaw@uaa.alaska.edu Yes/No Not 
sure 
Is all of the data (information) being obtained about deceased people?  (If No, skip the next question and go to 
RD1)  No 
In addition to information about the deceased people, are you also collecting information from living persons 
about their recollections of the deceased people?  (If No, stop here and go to RD 2)   
RD1) Does your project only involve existing data, information, documents, or samples that you will obtain from a 
publicly available source that does not require permission to access the data?  (If Yes, stop here and go to RD2.)  Yes 
Does a funding source (federal, state, or local), either directly (direct funder) or indirectly (secondary, or pass-
through funder) require IRB review?  (If Yes, stop here and go to RD3)    
Is any of the data (information) being obtained about individuals who are, or could be, living now?     
Is any of the data (information) being obtained, directly or indirectly, from living individuals?     
Are you observing people, directly or indirectly, to collect your information?     
Are you interacting (face-to-face, through telephone, electronic media or documents) with people?     
Is the data collected by intervening (taking measurements, samples, images) with people, or observing an 
intervention carried out by another person?     
Does the data/information you are collecting only center on things, quantities, or other questions about what item, 
process, or procedure is used?  (If Yes, stop here and go to RD2)    
Does the data/information you are collecting include the opinions, characteristics, or behavior of individuals?     
Does the data/information you are collecting include any information that could identify the individuals?     
Does the data/information you are using to recruit people for your project include any information that could 
identify the individual?     
During the process of collecting data, will you or any research team member, be able to identify the individuals?     
Will the data or information you are collecting examine, for example, the function of culture, expression of gender, 
or political views of members of the population in the study?     
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Could the results of this evaluation be used to make a general conclusion about the data/information you will 
collect?     
Is this evaluation connected to individual or group outcomes?     
Could the results of this evaluation impact the future use of similar programs, services, or public policy?     
Can this evaluation affect the development or implementation of other programs of a similar nature?     
 
   
Project Description:  The purpose of this project is to provide a class on guidelines to Psychiatric Mental Health Nurse Practitioners (PMH-NP’s). To improve PMH-NP adherence to screening for metabolic screening and monitoring of SMI patients taking second-generation antipsychotics (SGA’s). An educational class will be provided to voluntary participants.  Population:  The population of interest is Psychiatric Mental Health Practitioners because they mainly prescribe second-generation antipsychotic medications.  Plan:  The class will focus on national guidelines for SMI patients on SGA’s. A pre and posttest will be given to participants who attend the educational class. Only demographic information will be provided to the participants where they will not be individually identified.  All research conducted by University of Alaska Anchorage faculty, staff, or students, which involves human subjects must be reviewed by the Institutional Review Board (IRB). To determine if your project involves human subjects or is research under UAA IRB definitions, complete this form and send it to the UAA Research Compliance Officer, simumaw@uaa.alaska.edu. For help, contact the Office of Research Integrity & Compliance (ORIC): (907) 786-1099.  
Page 1 of 2 Last Revised 8/20/2015 
  
If you answered Not Sure for any question, briefly explain why you are 
uncertain. Briefly explain here. 
RD2 – Your work is most likely not human subject research and you do not need to complete 
the rest of the first section. Complete Section B and return the Request for IRB Determination 
form for a final confirmation.  
RD3 – Your work must be reviewed by the IRB. Go to IRBNet and complete a UAA IRB 
Proposal and all additional documents for IRB review.  
 
Section B – Instructions, tab to each box and complete the information. 
Name: Annabel Moreno          Today’s Date: 2/9/2016  
Affiliation with UAA (If this project will be used for class credit, complete the next two lines. If not, skip to 
Faculty/Staff):  
Student Level:  Graduate  Course Number:  Individual Scholarly Project NS 696  
  Faculty Advisor:  Cindy Jones, ANP-PMH  Department: Nursing/UAA  
Faculty    or   Staff    Department: Nursing  
Center, Program, or Institute:  Psychiatric-Mental Health Nurse Practitioner Program.  
Project Title: Metabolic Syndrome Screening in Serious Mental Illness Patients:  A Quality 
Improvement Project  
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For Office of Research Integrity & Compliance Use Only   
Final Determination:   HSR  Not HSR   
Statement of Findings:   Will interact with participants, conducting a pre/post-test, which would normally 
be considered HSR,  
But class is free and informational only, not for credit or required for a program, therefore project is 
not HSR.  
  Page 2 of 2 Last Revised 8/20/2015   
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Appendix I 
Providence IRB Waiver 
 
